Accessibility Menu
Cardiovascular Systems logo

Cardiovascular Systems(NASDAQ) CSII

This security has been delisted. This page is retained for historical reference.

Cardiovascular Systems last closing stock price
MetricPriceDate
Last closeUSD 20.002023-04-27
Cardiovascular Systems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.1%USD 19.982023-04-20
1 month+0.7%USD 19.862023-03-28
3 month+49.48%USD 13.382023-01-27
Year to date+46.84%USD 13.622022-12-30
1 year+0.15%USD 19.972022-04-27
3 year-52.53%USD 42.132020-04-27
5 year-13.64%USD 23.162018-04-27
Since inception+123.46%USD 8.952009-02-26

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

CSII Financials

Key Financial Metrics (TTM)

Gross Margin

73.14%

Operating Margin

-15.16%

Net Income Margin

-15.63%

Return on Equity

-14.19%

Return on Capital

-13.27%

Return on Assets

-11.45%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$173.63M

Operating Income

-$38.56M

EBITDA

-$33.84M

Operating Cash Flow

-$29.16M

Capital Expenditure

-$4.52M

Free Cash Flow

-$33.68M

Cash & ST Invst.

$132.00M

Total Debt

$20.12M

Cardiovascular Systems Performance Analysis

Cardiovascular Systems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 236,222,000N/A
Cardiovascular Systems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-03-31-4.9%
Q42022-06-3011.2%
Q12022-09-30-4.5%
Q22022-12-313.0%
Cardiovascular Systems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.94N/A
Cardiovascular Systems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-03-31-8.7%
Q42022-06-30N/A
Q12022-09-30-8.0%
Q22022-12-3125.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$61.45M

+3.9%

Gross Profit

$42.99M

+4.7%

Gross Margin

69.96%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

725

N/A

Net Income

-$7.89M

+12.0%

EBITDA

-$7.09M

+0.8%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$132.00M

-25.2%

Total Debt

$20.12M

-8.5%

Accounts Receivable

$40.23M

+15.1%

Inventory

$41.19M

+30.1%

Long Term Debt

$20.12M

-8.5%

Short Term Debt

$0.00

N/A

Return on Assets

-11.45%

N/A

Return on Invested Capital

-12.66%

N/A

Free Cash Flow

-$5.59M

-95.8%

Operating Cash Flow

-$3.55M

-131.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FNAParagon 28, Inc.
$13.09+0.00%
SILKSilk Road Medical, Inc
$27.49-0.04%
HARPHarpoon Therapeutics, Inc.
$23.01+0.09%
ICPTIntercept Pharmaceuticals, Inc.
$19.00+0.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.